Should you buy the GSK share price after last week’s 10% fall?
Should you buy the GSK share price after last week’s 10% fall? Fool.co.uk9 December 2018, 11:00 GMT. Until last week, 2018 had looked like being a good year for GlaxoSmithKline (LSE: GSK) shareholders. A surprise twist. However, the Horlicks announcement was followed less than four hours later by news that the firm had agreed to spend $5.1bn (£4bn) buying US pharma firm Tesaro. Between 2018 and 2020, “the acquisition of Tesaro and associated R&D and commercial investments” are expected to reduce Glaxo’s adjusted earnings by “mid-to-high single-digit percentages”. As a result, the firm has downgraded its guidance for the 2016-20 period.